NCT04384029

The Geneva Covid-19 CVD Study

Completed Last updated 19 October 2021

What this trial tests

trial testing Covid-19 + patients in COVID in 1,927 participants. Completed in 31 July 2021.

Timeline

24 March 2020

Primary endpoint
30 June 2021

31 July 2021

Quick facts

Lead sponsor	François MACH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,927
Start date	24 March 2020
Primary completion	30 June 2021
Estimated completion	31 July 2021
Sites	1 location across Switzerland

Drugs / interventions tested

• Covid-19 + patients

Conditions studied

• COVID — all drugs for COVID →
• CVD — all drugs for CVD →

Sponsor

François MACH

Who can join

18 and older, any sex, with COVID or CVD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators propose to analyse the clinical data of all patients admitted in Geneva University Hospitals (HUG) or in a care center in Geneva who are diagnosed with COVID-19. CVD being one of the most important risk factors for developing a severe form of the disease, the investigators will explore the prognosis and clinical outcomes of those patients according to their CVD history as well as newly onset CVD during hospitalization. Moreover, as further evidence is needed on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors for SARS-CoV-2 infected patients, the investigators will study prognosis and outcomes according to the patients' medications. Finally, the investigators propose to evaluate hospital length of stay and cost. The aim, therefore, is to collect information and scientific evidence from patients hospitalized and diagnosed positive for COVID-19, in order to evaluate if previous (or newly onset) CVD may influence outcomes and costs.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
   Raman B, Bluemke DA, Lüscher TF, Neubauer S. · · 2022 · cited 444× · PMID 35176758 · DOI 10.1093/eurheartj/ehac031
2. Mortality and high risk of major adverse events in patients with COVID-19 and history of cardiovascular disease.
   Tessitore E, Carballo D, Poncet A, Perrin N, et al · · 2021 · cited 24× · PMID 33833064 · DOI 10.1136/openhrt-2020-001526
3. Cardiovascular Therapy and Mortality in Hospitalized Patients With COVID-19: A Cohort Study
   Follonier C, Tessitore E, Handgraaf S, Carballo D, et al · · 2021 · DOI 10.2139/ssrn.3875394
4. Cardiovascular therapy use, modification, and in-hospital death in patients with COVID-19: A cohort study.
   Follonier C, Tessitore E, Handgraaf S, Carballo D, et al · · 2022 · PMID 36417470 · DOI 10.1371/journal.pone.0277653